Skye Bioscience Inc. Common Stock (SKYE)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Skye Bioscience at $1.53, a $54.2 million market value, on 2026-10-13. The business is a clinical-stage drug developer with no revenue in any filed period I was given. Its lead asset, nimacimab, targets CB1 receptors for obesity and metabolic disease, but that is a promise, not a proven franchise. From the filings, FY2025 net loss was $55.9 million, FY2024 was $26.6 million, and FY2023 was $37.6 million. In the quarter ended 2026-06-30, net loss was $10.8 million; in the quarter ended 2026-03-31, $12.5 million. Revenue is n/a throughout. Free cash flow is -$38.8 million trailing, so the company burns cash at a rate that demands financing. At the 2026-10-13 close, FairStock's FCF yield is -71.6%. The balance sheet shows low leverage—D/E 0.03—but that is small comfort against FairStock's negative ROE of -233.87%, ROCE of -95.06%, Piotroski 0/9, and Altman Z-Score -23.91. FairStock's P/B is 3.13 and P/E is -0.15, but negative earnings make those valuation measures noisy. Beta is 2.90, so the stock is volatile. FairStock score is 32/100, and the Lynch category is none because of losses in each of the last four years. I cannot identify a durable moat from these numbers; this is a binary research bet. The only real growth path is clinical success, partnership, or approval. Until then, the financials show a fragile, cash-consuming enterprise, not a Graham bargain. I would call it speculative, not investment-grade.

In plain English: Skye Bioscience is a small drug company with no product on the market, trying to develop a treatment for obesity and related metabolic diseases. The filings I was given show no revenue and large losses, and the company is using cash. At $1.53 on 2026-10-13, the price is not supported by current sales or profits, so it looks highly speculative rather than cheap or fairly valued.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer